Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021195544 - NOVEL ANUCLEATED CELLS FOR THE TREATMENT OF DISEASES

Publication Number WO/2021/195544
Publication Date 30.09.2021
International Application No. PCT/US2021/024442
International Filing Date 26.03.2021
IPC
A61K 35/12 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
A61K 35/14 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
A61K 35/19 2015.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
19Platelets; Megacaryocytes
C12M 1/00 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
C12M 1/26 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
26Inoculator or sampler
C12M 1/34 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
34Measuring or testing with condition measuring or sensing means, e.g. colony counters
CPC
A61K 35/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
19Platelets; Megacaryocytes
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
C12N 5/0644
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor;
06Animal cells or tissues; Human cells or tissues
0602Vertebrate cells
0634Cells from the blood or the immune system
0644Platelets; Megakaryocytes
G01N 2800/24
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
24Immunology or allergic disorders
G01N 33/564
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
564for pre-existing immune complex or autoimmune disease ; , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
Y02A 50/30
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection, e.g. against extreme weather
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applicants
  • PLATELET BIOGENESIS, INC. [US]/[US]
Inventors
  • HETT, Sunita R.
  • WEISINGER, Karen
  • PENG, Yang
  • MCLAUGHLIN, Kyle P.
  • PETERS, Christian G.
  • ZUKAUSKAS, Andrew R.
  • SMITH, Brenden W.
  • GIANNINI, Silvia
  • LEE, Po-Shun
Agents
  • FAYERBERG, Roman
Priority Data
17/213,79626.03.2021US
63/000,86627.03.2020US
63/024,64914.05.2020US
63/104,87123.10.2020US
63/125,49015.12.2020US
63/142,58628.01.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL ANUCLEATED CELLS FOR THE TREATMENT OF DISEASES
(FR) NOUVELLES CELLULES ANUCLÉÉES POUR LE TRAITEMENT DE MALADIES
Abstract
(EN) The present disclosure takes advantage of non-naturally existing, novel, anucleated platelets or platelet-like cells or platelet variants (collectively referred to as PECs) or derivatives thereof (i.e., genetically engineered), which share at least one common receptor, ligand or an antigen with endogenous cells that are targets for autoantibodies and effectuate their clearance. The present disclosure also takes advantage of viral adhesion or entry receptors or genetically engineered PECs or derivatives thereof, which are engineered to express viral adhesion or entry receptors, that specifically binds to viral proteins on viruses or viral particles and effectuate their clearance.
(FR) La présente invention tire profit de plaquettes existantes non naturelles, nouvelles ou anucléées, de cellules de type plaquettes, de variants de plaquettes (collectivement appelés PEC) ou de dérivés correspondants (c.-à-d., génétiquement modifiés), qui partagent au moins un récepteur cellulaire, un ligand ou un antigène commun avec des cellules endogènes qui sont des cibles pour des autoanticorps et exécutent leur clairance. La présente invention tire également profit de récepteurs cellulaires d'adhésion ou d'entrée viraux, de PEC génétiquement modifiés ou de dérivés correspondants, qui sont modifiés pour exprimer des récepteurs cellulaires d'adhésion ou d'entrée viraux, qui se lient spécifiquement à des protéines virales sur des virus ou à des particules virales et exécutent leur clairance.
Related patent documents
Latest bibliographic data on file with the International Bureau